Cite
MLA Citation
Rinat Yerushalmi et al.. “A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age.” Breast, vol. 41, n.d., pp. S12–. http://access.bl.uk/ark:/81055/vdc_100070082993.0x000029